Endocrine Therapy for Male Breast CancerIan S Fentiman*
Professor of Surgical Oncology, Research Oncology, Guy’s Hospital, London, UK
- *Corresponding Author:
- Ian S Fentiman
Professor of Surgical Oncology
Research Oncology, 3rd Floor Bermondsey Wing
Guy’s Hospital, London SE1 9RT, UK
E-mail: [email protected]
Received date: May 02, 2013; Accepted date: June 06, 2013; Published date: June 21, 2013
Citation: Fentiman IS (2013) Endocrine Therapy for Male Breast Cancer. J Steroids Horm Sci 4:112. doi:10.4172/2157-7536.1000112
Copyright: © 2013 Fentiman IS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
More than 90% of male breast cancers (MBC) are estrogen receptor positive but unfortunately over 40% are either stage III or stage IV at the time of presentation. This means that for a substantial proportion of patients, endocrine therapy will be used in a palliative role in the management of MBC. Tamoxifen is the main first line agent that is given for both adjuvant treatment and control of advanced disease. Although effective it can be more toxic in men than in women so that a significant proportion of males will become non-compliant. It is important that non-adherence is recognised and whenever possible second line therapy is instituted with either aromatase inhibitors or LHRH analogues. International collaboration in randomised trials will be necessary to determine the future endocrine therapies for MBC.